Presenter: Stanley Cohen, Metroplex Clinical Research Center, Dallas, Texas, USA.
Saturday 15 June: 08:00–09:00 (Abstract LB0004)
In ORAL Shift, patients with rheumatoid arthritis who achieved low disease activity (CDAI ≤10) during a 24-week period of treatment with the Janus kinase inhibitor tofacitinib plus methotrexate were randomly assigned to continue with both treatments or to receive tofacitinib plus placebo during the 24-week withdrawal phase. The primary outcome is change in DAS28-ESR score from the time of randomization to the end of the withdrawal phase.